CHAMPS clinical trial
Jump to navigation
Jump to search
Introduction
A clinical trial finding that betaseron (interferon-beta 1b) reduced the conversion from early possible multiple sclerosis (MS) to definite MS.
A clinical trial finding that betaseron (interferon-beta 1b) reduced the conversion from early possible multiple sclerosis (MS) to definite MS.